Full Text View
Tabular View
No Study Results Posted
Related Studies
Safety and Tolerability of 28 Days Treatment With Glycopyrrolate(NVA237) (100 or 200µg Once a Day) in Patients With Moderate to Severe COPD
This study has been completed.
Study NCT00510510   Information provided by Novartis
First Received: August 1, 2007   Last Updated: January 15, 2008   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Additional conditions recognized in this trial
Lung Diseases
Lung Diseases, Obstructive
Pulmonary Disease, Chronic Obstructive
Respiration Disorders
More general conditions related to this trial
Respiratory Tract Diseases
Interventions listed in this trial
Glycopyrrolate
More general drug interventions related to this trial
Adjuvants, Anesthesia
Central Nervous System Agents
Cholinergic Agents
Cholinergic Antagonists
Molecular Mechanisms of Pharmacological Action
Muscarinic Antagonists
Neurotransmitter Agents
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
Novartis


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services